Adding statin to carvedilol for cirrhosis with heart problems
Treatments studied
Part of Digestive system, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have cirrhosis (liver scarring) that is not causing severe symptoms like fluid buildup or confusion.
- You must have a specific heart condition called cirrhotic cardiomyopathy (detected on an ultrasound of the heart).
- You cannot have taken any statin (cholesterol-lowering drug) in the past month.
- You cannot have severe cirrhosis (a score above 9 on the Child-Turcotte-Pugh test) or other serious illnesses like kidney failure, heart disease, or certain infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
This study is looking at how cirrhosis affects the heart (called cirrhotic cardiomyopathy). It aims to understand the connection between advanced liver disease and heart function, which may help improve care for people with cirrhosis.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
This trial tests if adding midodrine to carvedilol is better than carvedilol alone at preventing another bleed from varices in patients with cirrhosis who have had a high-risk variceal bleed.
This trial tests whether carvedilol can prevent the first development of swollen veins (varices) in the esophagus in people with cirrhosis who do not have them yet. It may help lower the risk of future bleeding from those veins.
Hear when a new Decompensated Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.